Santhera Pharmaceuticals Holding AG (SWX:SANN)
12.20
-0.20 (-1.61%)
At close: Nov 28, 2025
SWX:SANN Revenue
Santhera Pharmaceuticals Holding AG had revenue of 24.01M CHF in the half year ending June 30, 2025, with 509.62% growth. This brings the company's revenue in the last twelve months to 49.02M, down -56.85% year-over-year. In the year 2024, Santhera Pharmaceuticals Holding AG had annual revenue of 39.12M, down -62.17%.
Revenue (ttm)
49.02M
Revenue Growth
-56.85%
P/S Ratio
3.33
Revenue / Employee
620.46K
Employees
79
Market Cap
163.08M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 39.12M | -64.30M | -62.17% |
| Dec 31, 2023 | 103.41M | 95.94M | 1,283.84% |
| Dec 31, 2022 | 7.47M | 9.07M | - |
| Dec 31, 2021 | -1.60M | -16.60M | - |
| Dec 31, 2020 | 15.01M | -60.37M | -80.09% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Roche Holding AG | 63.49B |
| Novartis AG | 44.95B |
| Sandoz Group AG | 8.42B |
| Alcon | 8.12B |
| Lonza Group AG | 7.09B |
| Galenica AG | 4.03B |
| Sonova Holding AG | 3.85B |
| Galderma Group AG | 3.73B |
Santhera Pharmaceuticals Holding AG News
- 26 days ago - Half Year 2025 Santhera Pharmaceuticals Holding AG Analyst Briefing Transcript - GuruFocus
- 7 weeks ago - Santhera Partners With Biomedica To Distribute Agamree In Russia - Nasdaq
- 2 months ago - Health Canada Approves Santhera's AGAMREE For Duchenne Muscular Dystrophy - Nasdaq
- 2 months ago - Santhera Pharmaceuticals Holding AG (SPHDF) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Santhera Pharmaceuticals Holding AG 2025 Q2 - Results - Earnings Call Presentation - Seeking Alpha
- 2 months ago - Santhera Pharma Stock Down On Wider H1 Loss; Is AGAMREE On Track? - Nasdaq
- 3 months ago - Santhera Enters into Agreement with Ikris Pharma Network for the Distribution of AGAMREE® (Vamorolone) in India - GlobeNewsWire
- 3 months ago - Santhera Secures Agreement with Uniphar for the Distribution of AGAMREE® (Vamorolone) in five GCC (Gulf Cooperation Council) Countries - GlobeNewsWire